Jesus Lovera, MD
Basic profileLouisiana State University Health Sciences Center New Orleans
Jesus Lovera is a Neurology physician affiliated with Louisiana State University Health Sciences Center New Orleans. OpenAlex indexes 47 publications with 1,529 citations (h-index 21); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2820 Napoleon Ave
Suite 700
New Orleans, LA 701156969
Telephone
504-412-1517Registry record last updated 29 Oct 2008.
Clinical trials
- Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
Sponsor: Louisiana State University Health Sciences Center in New Orleans
- Safety of Polyphenon E in Multiple Sclerosis Pilot Study
Sponsor: Louisiana State University Health Sciences Center in New Orleans
- Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Sponsor: Oregon Health and Science University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202529 payments
- Amgen Inc.Program year202513 payments
- TG Therapeutics, Inc.Program year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
47.2%Gabapentinoids11.1%Gabapentin71%Pregabalin23%Lyrica6%Part D<11 patientsSSRI5.2%Escitalopram Oxalate37%Trazodone Hcl21%Fluoxetine Hcl16%Sertraline Hcl12%Citalopram Hbr7%Paroxetine Er7%Part D<11 patients+ 18 more classes in this area
Cancer & immunology
25.5%CD20-directed Cytolytic Antibody7.1%Kesimpta Pen95%Ocrevus5%Part D<11 patientsOther immunosuppressants4.6%Dimethyl Fumarate88%Tecfidera13%Part D<11 patients+ 5 more classes in this area
Musculoskeletal
12.5%gamma-Aminobutyric Acid-ergic Agonist7.1%Baclofen100%Part D≥41 patientsCentral alpha-2 Adrenergic Agonist4%Tizanidine Hcl100%Part D≥25 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2008–2012 per NIH RePORTER. The latest:
- SAFETY AND NEUROPROTECTIVE EFFECTS OF POLYPHENON E IN MULTIPLE SCLEROSIS
Lsu Health Sciences Center
FY2012$108,164K23AT004433 - SAFETY AND NEUROPROTECTIVE EFFECTS OF POLYPHENON E IN MULTIPLE SCLEROSIS
Lsu Health Sciences Center
FY2011$108,164K23AT004433 - SAFETY AND NEUROPROTECTIVE EFFECTS OF POLYPHENON E IN MULTIPLE SCLEROSIS
Lsu Health Sciences Center
FY2010$105,800K23AT004433
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A single Center study of the Symbol Digit Modalities test as a screening tool for cognitive impairment in Parkinson’s disease
Clinical Parkinsonism & Related Disorders
2025 - The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis
Journal of the Neurological Sciences
2024 - - Considering race in biopsychosocial stress moderators of clinical outcomes of Multiple Sclerosis.
Psychoneuroendocrinology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Efrain Reisin, MD
Louisiana State University Health Sciences Center New Orleans
Abraham Gedalia, MD
Louisiana State University Health Sciences Center New Orleans
Meredith Clement, MD
Louisiana State University Health Sciences Center New Orleans
Peter Boggs, MD
Louisiana State University Health Sciences Center New Orleans
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”